SERES THERAPEUTICS, INC. (NASDAQ:MCRB) Files An 8-K Results of Operations and Financial Condition
Item2.02. Results of Operations and Financial Condition.
On May4, 2017, Seres Therapeutics, Inc. (the Company) announced
its financial results for the quarter ended March31, 2017. The
full text of the press release issued in connection with the
announcement is furnished as Exhibit 99.1 to this Current Report
on Form 8-K.
The information in this Item 2.02 of this Form 8-K (including
Exhibit 99.1) shall not be deemed filed for purposes of Section18
of the Securities Exchange Act of 1934, as amended (the Exchange
Act), or otherwise subject to the liabilities of that section,
nor shall it be deemed incorporated by reference in any filing
under the Securities Act of 1933, as amended, or the Exchange
Act, except as expressly provided by specific reference in such a
filing.
Item9.01. Financial Statements and Exhibits.
(d) Exhibits
The following exhibit relating to Item 2.02 shall be deemed to be
furnished, and not filed:
|
Exhibit No. |
Description |
|
| 99.1 | Press Release issued on May4, 2017 |
About SERES THERAPEUTICS, INC. (NASDAQ:MCRB)
Seres Therapeutics, Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. SER-109 is its lead product candidate, which is designed to prevent further recurrences of Clostridium difficile infection (CDI). The Company is developing additional product candidates, including SER-262 to prevent an initial recurrence of primary CDI, SER-287 to treat inflammatory bowel disease (IBD), including ulcerative colitis, and SER-155 to treat enteric bacterial pathogens. The Company is also conducting research on metabolic diseases, such as early-stage, non-insulin dependent diabetes; obesity and metabolic syndrome; other inflammatory diseases; cancer chemotherapy and immune suppression, and rare genetic diseases. SERES THERAPEUTICS, INC. (NASDAQ:MCRB) Recent Trading Information
SERES THERAPEUTICS, INC. (NASDAQ:MCRB) closed its last trading session down -0.02 at 9.77 with 207,550 shares trading hands.
